Rutgers scientists reveal structure of TB drug target and identify new inhibitors
Can't see this email? View it online
   
  April 18, 2017  
  Tuberculosis  
  The latest tuberculosis news from News Medical  
 Rutgers scientists reveal structure of TB drug target and identify new inhibitorsRutgers scientists reveal structure of TB drug target and identify new inhibitors
 
Rutgers University scientists have determined the three-dimensional structure of the target of the first-line anti-tuberculosis drug rifampin. They have also discovered a new class of potential anti-tuberculosis drugs that kill rifampin-resistant and multi-drug-resistant tuberculosis bacteria.
 
 
 LSTM scientists describe new approach to screening potential TB treatmentsLSTM scientists describe new approach to screening potential TB treatments
 
Scientists from LSTM's Research Centre for Drugs and Diagnostics (RCDD) have described in a paper published today in Scientific Reports, a new way of screening potential treatments for Tuberculosis (TB) which may assist in the identification and prioritisation of new therapies which could potentially reduce the duration of current TB treatment.
 
   Enhanced women's status linked to decline in solid fuel useEnhanced women's status linked to decline in solid fuel use
 
Globally, more people die each year of indoor air pollution than HIV, TB and malaria combined. So why is household air pollution such a neglected health issue and what needs to change in order to stop this "silent killer of women"?
 
   Innovate UK funds new, economic vaccine to halt spread of 'zoonotic' infectious diseasesInnovate UK funds new, economic vaccine to halt spread of 'zoonotic' infectious diseases
 
A team of international scientists led by Dr. Michael Jarvis at the University of Plymouth has received funding in excess of £408,000 from Innovate UK to develop a new and economic vaccine designed to halt the spread of highly pathogenic 'zoonotic' (spreading from animals to humans) infectious diseases.
 
 Epigem partners with Northumbria University to develop disposable TB testing kit
 
Epigem partners with Northumbria University to develop disposable TB testing kitLeading micro-engineering company Epigem today announced a new Knowledge Transfer Partnership with Northumbria University to develop a cost-effective tuberculosis (TB) testing kit.
 
 
 Genomic analysis technologies: past, present and future
 
Genomic analysis technologies: past, present and futureIllumina was founded in 1998. It was based on technology invented by Dr. David Walt that was licensed from Tufts University and formed the basis of our microarray business. The fundamental invention was a unique way to put beads in wells that were created on fiber optic bundles, with the beads being imaged through the fibers.